Technical Indicators and Signals
The stochastic oscillator indicator is the important indicator to compare the security price over a certain period of time. The stochastic %K of Exelixis, Inc. (NASDAQ:EXEL) for the period of 9-Day stands at 60.67% while the stochastic %D for the same period stands at 70.88%.
The 7-Day Average Directional Index ADX (also known as Trend Strength Indicator) of Exelixis, Inc. (NASDAQ:EXEL) signals “Buy” while other important signals like the 20-Day Moving Average Vs. Price signals “Sell”.
Another important signal of trend and momentum of a security is 20-50 Day MACD Oscillator or Moving Average Convergence Divergence signals “Buy” for Exelixis, Inc. (NASDAQ:EXEL) while 20-100 Day MACD Oscillator indicates “Buy”.
Bollinger band is a volatility indicator of a certain security, currently Exelixis, Inc. (NASDAQ:EXEL)’s 20-Day Bollinger Band indicates “Hold”.
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.
Previous Day Activity Analysis
On the last trading day, Exelixis, Inc. (NASDAQ:EXEL) opened the session at $26.28 and after going down -2.46% closed at $25.75. The stock lost -0.53 points in the last trade.
Exelixis, Inc. (NASDAQ:EXEL)’s stock fluctuated in the range of $25.50 and $26.30 during the previous active session. Exelixis, Inc. (NASDAQ:EXEL) traded with the volume of 2.82 Million with average volume of 3.87 Million. The stock has MEDIUM volatility on the last trading session.
Currently the Beta for the company remains at 1.88 while ATR (Average True Range) and RSI (Relative Strength Index) are at 1.3 and 46.85 respectively.
Currently the Insider Ownership of the shares of Exelixis, Inc. (NASDAQ:EXEL) is at 1% and the shares outstanding are 287.63 Million.
Important Ratio Analysis
Some important ratios to consider here for Exelixis, Inc. (NASDAQ:EXEL) are discussed below:
Price to Earnings P/E ratio stands at 52.23 while Forward P/E shows the value of 36.17.
The PEG ratio (Price to Earning to Growth) emits the value of 1.14. The Price to Sale P/S and Price to Book P/B shows the value of 18.06 and 31.79 respectively. While Price to Cash P/C and Price to Free Cash Flow P/FCF stands at 20.18 and 39.13 correspondingly.
The Quick Ratio of Exelixis, Inc. (NASDAQ:EXEL) stands at 4.3 while the Current Ratio depicts the value of 4.3.
Return on Assets ROA of Exelixis, Inc. (NASDAQ:EXEL) is at 26.1% whereas, Return on Equity ROE and Return of Investment ROI of Exelixis, Inc. (NASDAQ:EXEL) stand at 101.2% and -15.1% respectively.
Stock Performance Analysis
The stock performance of Exelixis, Inc. (NASDAQ:EXEL) on the basis of 5 day trade show the jump of 0.9% whereas, the monthly performance of the stock shows increase of 0.39%.
The quarterly performance of the stock remained in red zone with the value of -2.87% while six month performance of the shares of Exelixis, Inc. (NASDAQ:EXEL) remained bullish with the count of 19.16%.
The yearly and YTD performance of Exelixis, Inc. (NASDAQ:EXEL) remained up at 71.44% and 72.7% respectively.